New

Asia Pacific Acute Lung Injury Market

2021

Asia Pacific Acute Lung Injury Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Therapy (Mechanical Ventilation, Fluid Management, Pharmacotherapy, and Adjunctive Procedures) and End User (Hospitals, Ambulatory Surgery Centers, and Others)

Publication Month: Nov 2021 | Report Code: TIPRE00025718 | No. of Pages: 102 | Category: Pharmaceuticals | Status: Published

Market Insights

Asia Pacific Acute Lung Injury Market to Grow at a CAGR of 5.2% to reach US$ 174.61 million from 2021 to 2028

Covid
Assesing the covid-19 impact?
Get the Latest COVID-19 Analysis on this market
Request Now
Happy to join you in your fight against the COVID-19 economic pandemic!

The APAC acute lung injury market is expected to grow from US$ 122.16 million in 2021 to US$ 174.61 million by 2028; it is estimated to grow at a CAGR of 5.2% from 2021 to 2028.

China, India, Japan, South Korea, and Australia are major economies in APAC. Technological advancements by market players is expected to fuel the market growth. Manufacturers in the acute lung injury treatment market are focusing on the adoption of various strategies such as product innovation, product launches, and approvals, as well as R&D investment for advancements, along with inorganic strategies such as merger and acquisition and partnerships as their developmental strategies to maintain the competitive environment in the market. For instance, Faron Pharmaceuticals, Ltd. Is engaged in developing pharmacological treatments for ALI with the help of a consortium. The FP-1201-lyo treatment for acute lung injury is in the third phase of clinical trials and is anticipated to obtain authorization during the forecast period. Similarly, in November 2020, Novartis entered into an exclusive license with Mesoblast to manufacture, develop, and commercialize remestemcel-L to treat ARDS associated with COVID-19. Moreover, recent advances in understanding ALI pathophysiology have led to investigations of numerous potential pharmacologic treatments. In June 2020, Chimerix initiated a Phase II/III clinical trial to evaluate the safety and efficacy of Dociparstat sodium (DSTAT) in patients with ALI due to COVID-19. Therefore, the introduction of advanced products is likely to revolutionize and offer opportunities for the growth of the APAC acute lung injury market.

In case of COVID-19, APAC is highly affected specially India. As of September 2021, the COVID-19 cases reached 56.5 million in APAC, according to the United Nations Office for the Coordination of Humanitarian Affairs (UNOCHA). COVID-19 infection has been a serious problem in the patients with acute lung injury. According to the clinical data of infected patients in Asia, radiologic evidence of lung edema is common and deserves clinical attention. Lung edema is a manifestation of acute lung injury (ALI) and may progress to hypoxemia and potentially acute respiratory distress syndrome (ARDS). Patients diagnosed with ARDS and ALI have poorer prognosis and potentially higher mortality. Although no effective treatment is formally approved for COVID-19 infection, support of ventilation with oxygen therapy and sometimes mechanical ventilation is often required. Treatment with systemic and/or local glucocorticoids might be helpful to alleviate the pulmonary inflammation and edema, which may decrease the development and/or consequences of ARDS. For instance, a study combining data from China and Italy indicated that 27% of highly infected COVID-19 patients required assisted ventilation and had a 21% death rate. As a result, the acute lung injury market in the region has seen great expansion due to the COVID-19 impact.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the APAC acute lung injury market. The APAC acute lung injury market is expected to grow at a good CAGR during the forecast period.
APAC acute lung injury market

Get more information on this report :


APAC Acute Lung Injury Market Segmentation
APAC Acute Lung Injury Market – By Therapy

  • Mechanical Ventilation
  • Fluid Management
  • Pharmacotherapy
  • Adjunctive Procedures

APAC Acute Lung Injury Market – By End User

  • Hospitals
  • Ambulatory Surgery Centers
  • Others

APAC Acute Lung Injury Market, by Country

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC

APAC Acute Lung Injury Market - Companies Mentioned

  • Angion
  • GlaxoSmithKline Plc
  • ReAlta Life Sciences, Inc.
  • Stemedica Cell Technologies, Inc
  • Windtree Therapeutics, Inc.

TABLE OF CONTENTS

1. Introduction

1.1 Scope of the Study

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 APAC Acute Lung Injury Market – By Therapy

1.3.2 APAC Acute Lung Injury Market – By End User

1.3.3 APAC Acute Lung Injury Market– By Country

2. Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. APAC Acute Lung Injury Market– Market Landscape

4.1 Overview

4.2 APAC PEST Analysis

4.3 Experts Opinion

5. APAC Acute Lung Injury Market – Key Market Dynamics

5.1 Market Drivers

5.1.1 Increasing Prevalence of Respiratory Diseases

5.1.2 Rising Geriatric Population

5.2 Market Restraints

5.2.1 High Cost of Therapies

5.3 Market Opportunities

5.3.1 Technological Advancements by Market Players

5.4 Future Trends

5.4.1 Growing Pipeline Drugs

5.5 Impact Analysis

6. Acute Lung Injury Market– APAC Analysis

6.1 APAC Acute Lung Injury Market Revenue Forecast and Analysis

7. APAC Acute Lung Injury Market Analysis – By Therapy

7.1 Overview

7.2 APAC Acute Lung Injury Market Revenue Share, by Therapy (2021 and 2028)

7.3 Mechanical Ventilation

7.3.1 Overview

7.3.2 Mechanical Ventilation: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)

7.4 Fluid Management

7.4.1 Overview

7.4.2 Fluid Management: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)

7.5 Pharmacotherapy

7.5.1 Overview

7.5.2 Pharmacotherapy: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)

7.6 Adjunctive Procedures

7.6.1 Overview

7.6.2 Adjunctive Procedures: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)

8. APAC Acute Lung Injury Market Analysis – By End User

8.1 Overview

8.2 APAC Acute Lung Injury Market Revenue Share, by End User (2021 and 2028)

8.3 Hospitals

8.3.1 Overview

8.3.2 Hospitals: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)

8.4 Ambulatory Surgery Centers

8.4.1 Overview

8.4.2 Ambulatory Surgery Centers: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)

8.5 Others

8.5.1 Overview

8.5.2 Others: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)

9. APAC Acute Lung Injury Market – Country Analysis

9.1 APAC: Acute Lung Injury Market

9.1.1 Overview

9.1.2 APAC: Acute Lung Injury Market, by Country, 2021 & 2028 (%)

9.1.2.1 China: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.1.2.1.1 China: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.1.2.1.2 China: Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)

9.1.2.1.3 China: Acute Lung Injury Market, by End User, 2019–2028 (USD Million)

9.1.2.2 Japan: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.1.2.2.1 Japan: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.1.2.2.2 Japan: Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)

9.1.2.2.3 Japan: Acute Lung Injury Market, by End User, 2019–2028 (USD Million)

9.1.2.3 India: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.1.2.3.1 India: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.1.2.3.2 India: Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)

9.1.2.3.3 India: Acute Lung Injury Market, by End User, 2019–2028 (USD Million)

9.1.2.4 South Korea: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.1.2.4.1 South Korea: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.1.2.4.2 South Korea: Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)

9.1.2.4.3 South Korea: Acute Lung Injury Market, by End User, 2019–2028 (USD Million)

9.1.2.5 Australia: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.1.2.5.1 Australia: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.1.2.5.2 Australia: Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)

9.1.2.5.3 Australia: Acute Lung Injury Market, by End User, 2019–2028 (USD Million)

9.1.2.6 Rest of APAC: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.1.2.6.1 Rest of APAC: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

9.1.2.6.2 Rest of APAC: Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)

9.1.2.6.3 Rest of APAC: Acute Lung Injury Market, by End User, 2019–2028 (USD Million)

10. Impact Of COVID-19 Pandemic on APAC Acute Lung Injury Market

10.1 APAC: Impact Assessment of COVID-19 Pandemic

11. Industry Landscape

11.1 Overview

11.2 Organic Developments

11.2.1 Overview

11.3 Inorganic Developments

11.3.1 Overview

12. Company Profiles

12.1 GlaxoSmithKline Plc

12.1.1 Key Facts

12.1.2 Business Description

12.1.3 Products and Services

12.1.4 Financial Overview

12.1.5 SWOT Analysis

12.1.6 Key Developments

12.2 Stemedica Cell Technologies, Inc

12.2.1 Key Facts

12.2.2 Business Description

12.2.3 Products and Services

12.2.4 Financial Overview

12.2.5 SWOT Analysis

12.2.6 Key Developments

12.3 Windtree Therapeutics, Inc.

12.3.1 Key Facts

12.3.2 Business Description

12.3.3 Products and Services

12.3.4 Financial Overview

12.3.5 SWOT Analysis

12.3.6 Key Developments

12.4 ReAlta Life Sciences, Inc.

12.4.1 Key Facts

12.4.2 Business Description

12.4.3 Products and Services

12.4.4 Financial Overview

12.4.5 SWOT Analysis

12.4.6 Key Developments

12.5 Angion

12.5.1 Key Facts

12.5.2 Business Description

12.5.3 Products and Services

12.5.4 Financial Overview

12.5.5 SWOT Analysis

12.5.6 Key Developments

13. Appendix

13.1 About The Insight Partners

13.2 Glossary of Terms

LIST OF TABLES

Table 1. APAC Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

Table 2. China: Acute Lung Injury Market, by Therapy– Revenue and Forecast to 2028 (USD Million)

Table 3. China: Acute Lung Injury Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 4. Japan: Acute Lung Injury Market, by Therapy– Revenue and Forecast to 2028 (USD Million)

Table 5. Japan: Acute Lung Injury Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 6. India: Acute Lung Injury Market, by Therapy– Revenue and Forecast to 2028 (USD Million)

Table 7. India: Acute Lung Injury Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 8. South Korea: Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)

Table 9. South Korea: Acute Lung Injury Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 10. Australia: Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)

Table 11. Australia: Acute Lung Injury Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 12. Rest of APAC: Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)

Table 13. Rest of APAC: Acute Lung Injury Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 14. Organic Developments Done by Companies

Table 15. Inorganic Developments Done by Companies

Table 16. Glossary of Terms

LIST OF FIGURES

Figure 1. APAC Acute Lung Injury Market Segmentation

Figure 2. APAC Acute Lung Injury Market Segmentation, By Country

Figure 3. APAC Acute Lung Injury Market Overview

Figure 4. Mechanical Ventilation Segment Held the Largest Share of the Market in 2021

Figure 5. India to Show Significant Growth During Forecast Period

Figure 6. APAC PEST Analysis

Figure 7. APAC Acute Lung Injury Market Impact Analysis of Driver and Restraints

Figure 8. APAC Acute Lung Injury Market– Revenue Forecast and Analysis

Figure 9. APAC Acute Lung Injury Market Revenue Share, by Therapy (2021 and 2028)

Figure 10. APAC Mechanical Ventilation: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)

Figure 11. APAC Fluid Management: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)

Figure 12. APAC Pharmacotherapy: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)

Figure 13. APAC Adjunctive Procedures: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)

Figure 14. APAC Acute Lung Injury Market Revenue Share, by End User (2021 and 2028)

Figure 15. APAC Hospitals: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)

Figure 16. APAC Ambulatory Surgery Centers: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)

Figure 17. APAC Others: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)

Figure 18. APAC: Acute Lung Injury Market, by Key Country – Revenue (2021) (USD Million)

Figure 19. APAC: Acute Lung Injury Market, by Country, 2021 & 2028 (%)

Figure 20. China: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

Figure 21. Japan: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

Figure 22. India: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

Figure 23. South Korea: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

Figure 24. Australia: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

Figure 25. Rest of APAC: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)

Figure 26. Impact of COVID-19 Pandemic on APAC Country Markets

  1. Angion
  2. GlaxoSmithKline Plc
  3. ReAlta Life Sciences, Inc.
  4. Stemedica Cell Technologies, Inc
  5. Windtree Therapeutics, Inc.
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the APAC acute lung injury market.    
  • Highlights key business priorities in order to assist companies to realign their business strategies
  • The key findings and recommendations highlight crucial progressive industry trends in the APAC acute lung injury market, thereby allowing players across the value chain to develop effective long-term strategies    
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
  • Scrutinize in-depth APAC market trends and outlook coupled with the factors driving the acute lung injury market, as well as those hindering it 
  • Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution  
TIPRE00025718
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing
Request for Sample
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.